TY - JOUR
T1 - Simultaneous PET/MRI assessment of response to cytotoxic and hormone neo-adjuvant chemotherapy in breast cancer
T2 - a preliminary report
AU - Romeo, Valeria
AU - D’Aiuto, Massimiliano
AU - Frasci, Giuseppe
AU - Imbriaco, Massimo
AU - Nicolai, Emanuele
PY - 2017/2/1
Y1 - 2017/2/1
N2 - The aim of this study was to assess the response to cytotoxic and hormone neo-adjuvant chemotherapy in four patients with locally advanced breast cancer by simultaneous PET/MRI. Four patients with locally advanced breast cancer underwent simultaneous PET/MRI of the breast using a 3 T Biograph mMR before and after neo-adjuvant chemotherapy (two patients were treated with hormone-therapy and two patients were treated with cytotoxic chemotherapy). Morpho-structural tumoral features and tumor size were assessed; area value, metabolic (SUV and MTV) and functional (ADC, Ktrans, Ve, kep and iAUC) data were obtained by positioning regions of interest. A comparison of all parameters between the pre- and post-treatment PET/MRI examinations and between the two different therapeutic schedules was assessed. In patients treated with cytotoxic chemotherapy and classified as PR, there was a significant reduction of post-treatment morphological, metabolic and functional parameters. In a patient treated with hormone therapy, classified as SD, there was an increase of all post-treatment perfusion parameters, a substantially stable ADC value and a poor reduction of lesion size and of maximum SUV (SUVmax) values; the last patient, treated with hormone therapy and classified as PR, showed a significant reduction of lesion size and SUVmax values with a reduction of perfusion parameters and substantially stable ADC values. Multiparametric evaluation with simultaneous PET/MRI could be a useful tool to assess the response to cytotoxic and hormone neo-adjuvant chemotherapy in patients with breast cancer. Future studies in a larger cohort of patients are warranted to confirm the results of this preliminary study.
AB - The aim of this study was to assess the response to cytotoxic and hormone neo-adjuvant chemotherapy in four patients with locally advanced breast cancer by simultaneous PET/MRI. Four patients with locally advanced breast cancer underwent simultaneous PET/MRI of the breast using a 3 T Biograph mMR before and after neo-adjuvant chemotherapy (two patients were treated with hormone-therapy and two patients were treated with cytotoxic chemotherapy). Morpho-structural tumoral features and tumor size were assessed; area value, metabolic (SUV and MTV) and functional (ADC, Ktrans, Ve, kep and iAUC) data were obtained by positioning regions of interest. A comparison of all parameters between the pre- and post-treatment PET/MRI examinations and between the two different therapeutic schedules was assessed. In patients treated with cytotoxic chemotherapy and classified as PR, there was a significant reduction of post-treatment morphological, metabolic and functional parameters. In a patient treated with hormone therapy, classified as SD, there was an increase of all post-treatment perfusion parameters, a substantially stable ADC value and a poor reduction of lesion size and of maximum SUV (SUVmax) values; the last patient, treated with hormone therapy and classified as PR, showed a significant reduction of lesion size and SUVmax values with a reduction of perfusion parameters and substantially stable ADC values. Multiparametric evaluation with simultaneous PET/MRI could be a useful tool to assess the response to cytotoxic and hormone neo-adjuvant chemotherapy in patients with breast cancer. Future studies in a larger cohort of patients are warranted to confirm the results of this preliminary study.
KW - Breast cancer
KW - Neo-adjuvant chemotherapy
KW - Simultaneous PET/MRI
UR - http://www.scopus.com/inward/record.url?scp=85007607701&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85007607701&partnerID=8YFLogxK
U2 - 10.1007/s12032-016-0876-z
DO - 10.1007/s12032-016-0876-z
M3 - Article
C2 - 28035580
AN - SCOPUS:85007607701
SN - 1357-0560
VL - 34
JO - Medical Oncology
JF - Medical Oncology
IS - 2
M1 - 18
ER -